The future of hereditary angiodema treatment seems to be coming down to how many shots it takes to reduce attacks. Gene ...

As zanidatamab awaits an FDA approval decision, Jazz Pharmaceuticals is sharing long-term phase 2b data in advanced biliary ...

Adaptimmune was facing a financing cliff until Galapagos walked in with a sprawling licensing deal for a next-generation ...

We can now envision the oasis that Ionis Pharmaceuticals saw with its hereditary angioedema data. | We can now envision the ...

ACLA said the agency overstepped when it announced it would regulate all in vitro diagnostics with the same approach it uses ...

After announcing it would start selling its assets earlier this year, along with laying off nearly half the company, the ...

The brain-computer interface startup Precision Neuroscience said it has claimed the world record for the number of electrodes ...

Purple Biotech hopes its lead asset against metastatic pancreatic cancer will one day show its true colors as a potential ...

Ultragenyx is gearing up to take its glycogen storage disease (GSD) treatment to regulators next year after the gene therapy ...

Johnson & Johnson’s oral add-on drug significantly improved depressive symptoms and sleep outcomes in a phase 3 trial for ...

Immunovant’s decision to prioritize a next-gen FcRn antibody over phase 3 myasthenia gravis (MG) prospect batoclimab means ...